Nitric oxide (SB 204)

Drug Profile

Nitric oxide (SB 204)

Alternative Names: NVN-1000; SB-204

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator Novan Inc
  • Class Antiacnes; Antiandrogens; Antibacterials; Antihypertensives; Antivirals; Free radicals; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Androgen receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Genital warts
  • Discontinued Staphylococcal infections

Most Recent Events

  • 17 Jan 2017 Nitric oxide (SB 204) licensed to Sato Pharmaceutical in Japan
  • 14 Nov 2016 Novan announces intention to submit NDA to the US FDA in 2017
  • 28 Sep 2016 Novan completes enrolment in its two parallel phase III trials for Acne vulgaris (In children, In adolescents, In adults, In the elderly) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top